Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 12/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.52 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.52 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248451 | 1.00 | PAOX (0.70) | PAOXALDH1A1TSHRKDM4AKDM4C | |
| SCHEMBL25907273 | 1.00 | PAOX (0.70) | PAOXALDH1A1TSHRKDM4AKDM4C | |
| SCHEMBL18154617 | 1.00 | PAOX (0.70) | PAOXALDH1A1TSHRKDM4AKDM4C | |
| SCHEMBL2036849 | 0.97 | PAOX (0.67) | PAOXALDH1A1TSHRKDM4AKDM4C | |
| SCHEMBL805274 | 0.90 | — | — | |
| SCHEMBL16359464 | 0.83 | DNM1 (0.68) | PAOXKDM4AKDM4CKDM5AKDM7A | |
| Acetic Acid SCHEMBL19856511 | 0.81 | ALDH1A1 (0.65) | PAOXALDH1A1TSHRKDM4AKDM4C | |
| SCHEMBL22788743 | 0.81 | PAOX (0.50) | PAOXALDH1A1KDM4AKDM4CKDM5A | |
| SCHEMBL16723870 | 0.81 | PAOX (0.72) | PAOXALDH1A1TSHR | |
| SCHEMBL2775487 | 0.81 | PAOX (0.72) | PAOXALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8952055-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | NPPA, PARN, PARG | PAOX 3489/4885ALDH1A1 3477/4885TSHR 423/4885 |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | PAOX 2998/4885ALDH1A1 677/4885TSHR 2877/4885 |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | PAOX 3935/4885ALDH1A1 2332/4885TSHR 2134/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | PAOX 3935/4885ALDH1A1 2332/4885TSHR 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.